IFN-λ家族基因遗传多态性与HBV感染、病毒复制及清除的关系

doi:10.13345/j.cjb.210310

科微学术

生物工程学报

首页 > 过刊浏览>2022年第38卷第3期 >893-902. DOI:10.13345/j.cjb.210310

PDF HTML阅读 XML下载导出引用引用提醒

IFN-λ家族基因遗传多态性与HBV感染、病毒复制及清除的关系
DOI:
                        10.13345/j.cjb.210310
                    
CSTR:
                        32114.14.j.cjb.210310
                    
作者:
                        郑克溪郑克溪
昆明理工大学 生命科学与技术学院, 云南 昆明 650500
在期刊界中查找
在百度中查找
在本站中查找
张阿梅张阿梅
昆明理工大学 生命科学与技术学院, 云南 昆明 650500
在期刊界中查找
在百度中查找
在本站中查找

                    
作者单位:
作者简介:
通讯作者:
中图分类号:
基金项目:国家自然科学基金(81760364)；云南省中青年学术和技术带头人后备人才项目(2019HB002)

Correlations between genetic polymorphism of IFN-λ family gene and HBV infection,virus replication and clearance

Author:

ZHENG Kexi
ZHENG Kexi
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, China
在期刊界中查找
在百度中查找
在本站中查找
ZHANG A-Mei
ZHANG A-Mei
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, China
在期刊界中查找
在百度中查找
在本站中查找

Affiliation:

Fund Project:

摘要

图/表

访问统计

参考文献 [56]

相似文献

引证文献

资源附件

文章评论

摘要:

乙型肝炎病毒(hepatitis B virus,HBV)感染是一个严重的全球性公共卫生问题。HBV感染后会引发肝炎，可进一步发展为肝硬化甚至恶化为肝癌。干扰素λ(interferon λ,IFN-λ)是干扰素家族的成员之一，是抗病毒防御的重要细胞因子。IFN-λ家族包括4个成员，分别为IFN-λ1、IFN-λ2、IFN-λ3和IFN-λ4，已有研究表明该家族基因的遗传多态性与HBV的复制和患者的治疗效果具有相关性。文中从遗传易感的角度总结了IFN-λ家族基因多态性在HBV的感染、患者的病程进展和治疗效果中扮演的角色，从而进一步了解其遗传多态性在HBV感染及其病程中的作用，为HBV感染的预防与患者的治疗提供理论基础，为该类细胞因子作为抗HBV药物的研发提供参考。

关键词:乙型肝炎病毒;干扰素λ;病程进展;治疗效果

Abstract:

Hepatitis B virus (HBV) infection is one of the most serious public health problems.HBV infection could lead to hepatitis B,and even further develop into hepatic cirrhosis and hepatocellular carcinoma.Interferon lambda (IFN-λ) is a member of the interferon (IFN) family and an important cytokine for antiviral defense.There are four members in IFN-λ family,including IFN-λ1,IFN-λ2,IFN-λ3,and IFN-λ4.The genetic polymorphisms in the IFN-λ genes are associated with HBV replication and treatment response of HBV patients.In this review,we summarized the roles of genetic polymorphisms of the IFN-λ genes played in HBV infection,disease progression and treatment,with the aim to better understand their function.This review could serve as a reference for the HBV prevention and treatment of HBV patients,as well as for future clinical usage.

Key words:hepatitis B virus;interferon λ;progression of disease;treatment effect

参考文献

[1] Nicolini LA, Orsi A, Tatarelli P, et al. A global view to HBV chronic infection:evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals. Int J Environ Res Public Health, 2019, 16(18):E3307.

[2] W.H.O. WHO Guidelines Approved by the Guidelines Review Committee, in WHO Guidelines on Hepatitis B and C Testing. 2017, World Health Organization Copyright ? World Health Organization 2017, Geneva.

[3] Liang TJ. Hepatitis B:the virus and disease. Hepatology, 2009, 49(5 suppl):S13-S21.

[4] Soriano V, Barreiro P, Benitez L, et al. New antivirals for the treatment of chronic hepatitis B. Expert Opin Investig Drugs, 2017, 26(7):843-851.

[5] Zhang Z, Wang C, Liu Z, et al. Host genetic determinants of hepatitis B virus infection. Front Genet, 2019, 10:696.

[6] Akcay IM, Katrinli S, Ozdil K, et al. Host genetic factors affecting hepatitis B infection outcomes:insights from genome-wide association studies. World J Gastroenterol, 2018, 24(30):3347-3360.

[7] Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type Ⅰ and type Ⅲ interferons. Immunity, 2019, 50(4):907-923.

[8] Isaacs A, Lindenmann J. Virus interference. Ⅰ. The interferon. Proc R Soc Lond B, 1957, 147(927):258-267.

[9] Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class Ⅱ cytokine receptor complex. Nat Immunol, 2003, 4(1):69-77.

[10] Hamming OJ, Gad HH, Paludan S, et al. Lambda interferons:new cytokines with old functions. Pharmaceuticals (Basel), 2010, 3(4):795-809.

[11] Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class Ⅱ cytokine receptor IL-28R. Nat Immunol, 2003, 4(1):63-68.

[12] Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3(IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 2013, 45(2):164-171.

[13] Donnelly RP, Kotenko SV. Interferon-lambda:a new addition to an old family. J Interferon Cytokine Res, 2010, 30(8):555-564.

[14] O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4:the paradoxical new member of the interferon lambda family. J Interf Cytokine Res, 2014, 34(11):829-838.

[15] Gad HH, Dellgren C, Hamming OJ, et al. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem, 2009, 284(31):20869-20875.

[16] Galani IE, Triantafyllia V, Eleminiadou EE, et al. Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity, 2017, 46(5):875-890.e6.

[17] Lazear HM, Daniels BP, Pinto AK, et al. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med, 2015, 7(284):284ra59.

[18] Tian RR, Guo HX, Wei JF, et al. IFN-λ inhibits HIV-1 integration and post-transcriptional events in vitro, but there is only limited in vivo repression of viral production. Antivir Res, 2012, 95(1):57-65.

[19] Chen YQ, Wang YR, Tang RH, et al. Dendritic cells-derived interferon-λ1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesis. Cell Death Dis, 2020, 11:414.

[20] Li YY, Zhao L, Luo ZC, et al. Interferon-λ attenuates rabies virus infection by inducing interferon-stimulated genes and alleviating neurological inflammation. Viruses, 2020, 12(4):405.

[21] Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet, 2009, 41(10):1100-1104.

[22] Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009, 41(10):1105-1109.

[23] Hamming OJ, Terczyńska-Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J, 2013, 32(23):3055-3065.

[24] Eslam M, McLeod D, Kelaeng KS, et al. IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet, 2017, 49(5):795-800.

[25] Ray K. Deciphering the role of IFNλ subclasses in hepatic inflammation and fibrosis. Nat Rev Gastroenterol Hepatol, 2017, 14(6):326.

[26] Romani S, Hosseini SM, Mohebbi SR, et al. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Viral Hepat, 2017, 24(9):776-788.

[27] Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol, 2005, 79(6):3851-3854.

[28] Pagliaccetti NE, Chu EN, Bolen CR, et al. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology, 2010, 401(2):197-206.

[29] Sun H, Bi L, Zhou J, et al. Modulation of the function of dendritic cells in adolescents with chronic HBV infection by IFN-λ1. Int J Clin Exp Pathol, 2015, 8(2):1743-1751.

[30] Bockmann JH, Stadler D, Xia Y, et al. Comparative analysis of the antiviral effects mediated by type Ⅰ and Ⅲ interferons in hepatitis B virus-infected hepatocytes. J Infect Dis, 2019, 220(4):567-577.

[31] Makjaroen J, Somparn P, Hodge K, et al. Comprehensive proteomics identification of IFN-λ3-regulated antiviral proteins in HBV-transfected cells. Mol Cell Proteomics, 2018, 17(11):2197-2215.

[32] Yamada N, Murayama A, Shiina M. Anti-viral effects of interferon-λ3 on hepatitis B virus infection in cell culture. Hepatol Res, 2020, 50(3):283-291.

[33] Guo XY, Chen DK, Cai QX, et al. Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line. BMC Mol Cell Biol, 2020, 21(1):6.

[34] Cao YH, Zhang R, Zhang W, et al. IL-27, a cytokine, and IFN-λ1, a type Ⅲ IFN, are coordinated to regulate virus replication through type I IFN. J Immunol, 2014, 192(2):691-703.

[35] Giersch K, Homs M, Volz T, et al. Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice. Sci Rep, 2017, 7(1):3757.

[36] Cheng X, Xia Y, Serti E, et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology, 2017, 66(6):1779-1793.

[37] Cheng XM, Uchida T, Xia YC, et al. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Investig, 2020, 130(6):3205-3220.

[38] Zhang Z, Filzmayer C, Ni Y, et al. Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. J Hepatol, 2018, 69(1):25-35.

[39] Tham CYL, Kah J, Tan AT, et al. Hepatitis delta virus acts as an immunogenic adjuvant in hepatitis B virus-infected hepatocytes. Cell Rep Med, 2020, 1(4):100060.

[40] Grzegorzewska AE,Świderska MK, Mostowska A, et al. Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients. Vaccine, 2016, 34(41):4866-4874.

[41] Grzegorzewska AE, Winnicka H, Warchoł W, et al. Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients. Vaccine, 2018, 36(30):4454-4461.

[42] Grzegorzewska AE,Świderska MK, Marcinkowski W, et al. Polymorphism rs368234815 of interferon-λ4 gene and generation of antibodies to hepatitis B virus surface antigen in extracorporeal dialysis patients. Expert Rev Vaccines, 2020, 19(3):293-303.

[43] Song Y, Shen Y, Xia X, et al. Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals. PeerJ, 2017, 5:e4149.

[44] Zhang Y, Zhu SL, Chen J, et al. Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. Onco Targets Ther, 2016, 9:3249-3257.

[45] Qin S, Wang J, Zhou C, et al. The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection:an updated meta-analysis. Medicine (Baltimore), 2019, 98(38):e17275.

[46] Zhao J, Zhang X, Fang L, et al. Association between IL28B polymorphisms and outcomes of hepatitis B virus infection:a meta-analysis. BMC Med Genet, 2020, 21(1):88.

[47] Chen H, Fan JH, Chen WX, et al. Association of HLA-DQ and IFNL4 polymorphisms with hepatitis B virus infection and clearance. Chin J Hepatol, 2017, 25(7):506-511.

[48] Ma N, Zhang X, Yang L, et al. Role of functional IFNL4, IFNLR1, IFNA, IFNAR2 polymorphisms in hepatitis B virus-related liver disease in Han Chinese population. J Viral Hepat, 2018, 25(3):306-313.

[49] Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology, 2012, 142(3):513-520.e1.

[50] Galmozzi E, Viganò M, Lampertico P. Systematic review with meta-analysis:do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther, 2014, 39(6):569-578.

[51] Domagalski K, Pawłowska M, Zaleśna A, et al. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World J Gastroenterol, 2016, 22(41):9186-9195.

[52] Wei L, Wedemeyer H, Liaw YF, et al. No association between IFNL3(IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or-negative chronic hepatitis B. PLoS One, 2018, 13(7):e0199198.

[53] Vergori A, Rossetti B, Vicenti I, et al. Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection. Le Infezioni Med:Rivista Period Di Eziologia Epidemiol Diagn Clin E Terapia Delle Patologie Infettive, 2020, 28(4):576-586.

[54] Limothai U, Wasitthankasem R, Poovorawan Y, et al. Single nucleotide polymorphism of interferon lambda-4 gene is not associated with treatment response to pegylated interferon in Thai patients with chronic hepatitis B. Asian Pac J Cancer Prev, 2015, 16(13):5515-5519.

[55] Galmozzi E, Facchetti F, Grossi G, et al. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients. Liver Int, 2018, 38(3):417-423.

[56] 张迎明,申爽,田飞,等. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析.实用肝脏病杂志, 2019, 22(6):828-831. Zhang YM, Shen S, Tian F, et al. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in patients with chronic hepatitis B. J Pract Hepatol, 2019, 22(6):828-831(in Chinese).